Kenneth Hallows

Has grant

Professor and Chief

University of Southern California

United States

Research Interests

Explore related searches

Professors in United States Professors in Drug Delivery Drug Delivery professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Kenneth Hallows is the Chief at the University of Southern California. His research focuses on genetic kidney disease, addressing therapeutic strategies such as drug delivery applications and the modulation of gene expression through urinary extracellular vesicles. Recent articles highlight his work on the protective role of kidney-specific AMPK activity and advancements in kidney organoid modeling.

Recent Grants

Grant: Close

Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease (Clinical Trial Award)

Open Date: 2015-09-01

Close Date: 2020-09-01

Grant: Close

Cellular Energy Pathways as Novel Targets for the Therapy of Autosomal Dominant Polycystic Kidney Disease (Investigator-Initiated Research Award)

Open Date: 2015-09-01

Close Date: 2018-08-01

Grant: Close

Mechanisms and Relevance of Sodium Transport Regulation by AMPK

Open Date: 2012-08-01

Close Date: 2017-07-01

Articles (15)

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2020

Year:

View details

Matthew Thornton

University of Southern California

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Kenneth Hallows

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (15)

Therapeutic potential of urinary extracellular vesicles in delivering functional proteins and modulating gene expression for genetic kidney disease

Long-term expandable mouse and human-induced nephron progenitor cells enable kidney organoid maturation and modeling of plasticity and disease.

Investigation of Basolateral Targeting Micelles for Drug Delivery Applications in Polycystic Kidney Disease

Female Protection Against Diabetic Kidney Disease Is Regulated by Kidney-Specific AMPK Activity

Oral delivery of nanomedicine for genetic kidney disease

Association of Longitudinal Urinary Metabolic Biomarkers With ADPKD Severity and Response to Metformin in TAME-PKD Clinical Trial Participants

In vitro delivery of mTOR inhibitors by kidney-targeted micelles for autosomal dominant polycystic kidney disease

Effects of Hydrochlorothiazide and Metformin on Aquaresis and Nephroprotection by a Vasopressin V2 Receptor Antagonist in ADPKD

Metformin improves relevant disease parameters in an autosomal dominant polycystic kidney disease mouse model

Beneficial effects of bempedoic acid treatment in polycystic kidney disease cells and mice

Association of Baseline Urinary Metabolic Biomarkers with ADPKD Severity in TAME-PKD Clinical Trial Participants

Oral delivery of metformin by chitosan nanoparticles for polycystic kidney disease

AMPK is activated during lysosomal damage via a galectin-ubiquitin signal transduction system

AMPK, a Regulator of Metabolism and Autophagy, Is Activated by Lysosomal Damage via a Novel Galectin-Directed Ubiquitin Signal Transduction System

Activation of AMP-activated protein kinase during sepsis/inflammation improves survival by preserving cellular metabolic fitness

Collaborators (6)

Stephen Seliger

Ronald D. Perrone

jingyue jia

Qi-Long Ying

Eun Ji Chung

Matthew Thornton

Make your next move.